Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560114 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4METAP1PARP10PARP11 | |
| Hydrochloric Acid SCHEMBL3118573 | 0.98 | CHRNB2 (0.39) | CHRNB2CHRNA4METAP1PARP10PARP11 | |
| SCHEMBL12773143 | 0.83 | PARP10 (0.46) | CHRNB2CHRNA4METAP1PARP10PARP11 | |
| SCHEMBL1001109 | 0.82 | ASIC3 (0.60) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL29587394 | 0.82 | PNMT (0.60) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL3240344 | 0.82 | PNMT (0.60) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL29587818 | 0.81 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL21331206 | 0.81 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL11344972 | 0.79 | CYP1A2 (0.56) | CHRNB2CHRNA4CYP1A2CYP2A6MEN1 | |
| SCHEMBL7865689 | 0.79 | ASIC3 (0.47) | PARP10PARP11PARP1PNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-05-17 | — | — | US | claimed |
| EP-3728248-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-02-02 | — | — | EP | claimed |
| US-20200392133-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-17 | — | — | US | claimed |
| EP-3728248-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2020-10-28 | — | — | EP | claimed |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | UNIV ANTWERPEN (BE) | 2025-11-20 | — | — | US | disclosed |
| CN-119243183-A | Synthesis method of nitrosamine organic compound | 中国科学技术大学 | 2025-01-03 | — | — | CN | disclosed |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2024-09-19 | — | — | US | disclosed |
| US-20240231230-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM | NISSAN CHEMICAL CORPORATION (JP) | 2024-07-11 | — | — | US | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-11858900-B2 | Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives | OCUTERRA THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023233024-A1 | DPP9 BINDING COMPOUNDS | UNIVERSITEIT ANTWERPEN (BE) | 2023-12-07 | — | — | WO | disclosed |
| US-5869518-A | USEFUL IN THE TREATMENT OF OBESITY AND HYPERGLYCEMIA | SYNTHELABO (FR) | 1999-02-09 | — | — | US | disclosed |
| CN-1188478-A | Azacycloalcane derivatives, preparation thereof and their applications in therapy | SYNTHELABO (FR) | 1998-07-22 | — | — | CN | disclosed |
| EP-0823912-A1 | AZACYCLOALCANE DERIVATIVES, PREPARATION THEREOF AND THEIR APPLICATIONS IN THERAPY | SYNTHELABO (FR) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034870-A1 | AZACYCLOALCANE DERIVATIVES, PREPARATION THEREOF AND THEIR APPLICATIONS IN THERAPY | SYNTHELABO (FR) | 1996-11-07 | — | — | WO | disclosed |
| US-5326760-A | Aminobutanoic acid compounds having metalloprotease inhibiting properties | GLAXO, INC. (US) | 1994-07-05 | — | — | US | disclosed |
| US-4954590-A | SUBJECTING ISOINDOLINE ISOINDOLE COMPOUND TO OXIDATIVE POLYMERIZATION; ELECTROCONDUCTIVE POLYMER | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1990-09-04 | — | — | US | disclosed |
| US-4833231-A | Polymer having isoindole structure | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1989-05-23 | — | — | US | disclosed |
| EP-0248915-A1 | POLYMERS HAVING ISOINDOLE STRUCTURE AND PROCESS FOR THEIR PREPARATION | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | ROCK1, ROCK2, RHOA | CHRNB2 1273/4885CHRNA4 1909/4885METAP1 1481/4885 |
| US-11858900-B2 | Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives | KCNQ2, KCNQ1, KCNQ3 | CHRNB2 502/4885CHRNA4 261/4885METAP1 2811/4885 |
| US-20200392133-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | CHRNB2 1273/4885CHRNA4 1909/4885METAP1 1481/4885 |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | DPP9, DPP7, DPP3 | CHRNB2 4637/4885CHRNA4 4752/4885METAP1 46/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | CHRNB2 3736/4885CHRNA4 3015/4885METAP1 1392/4885 |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | CHRNB2 3043/4885CHRNA4 2677/4885METAP1 1488/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CHRNB2 2690/4885CHRNA4 4786/4885METAP1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.